Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Barclays PLC

Barclays PLC lifted its stake in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 126.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 318,910 shares of the company's stock after acquiring an additional 178,179 shares during the period. Barclays PLC owned 0.14% of Sana Biotechnology worth $1,325,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in shares of Sana Biotechnology by 16.3% during the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company's stock worth $131,494,000 after purchasing an additional 4,438,949 shares during the last quarter. State Street Corp grew its stake in Sana Biotechnology by 4.2% in the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company's stock worth $27,570,000 after acquiring an additional 269,274 shares during the period. Geode Capital Management LLC raised its holdings in Sana Biotechnology by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company's stock valued at $13,175,000 after acquiring an additional 276,055 shares during the last quarter. Integral Health Asset Management LLC lifted its stake in shares of Sana Biotechnology by 22.4% during the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company's stock worth $6,552,000 after purchasing an additional 220,000 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Sana Biotechnology by 11.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company's stock worth $4,359,000 after purchasing an additional 105,382 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company's stock.

Insider Transactions at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of the firm's stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. This trade represents a 6.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 31.10% of the company's stock.

Sana Biotechnology Trading Down 5.5 %

NASDAQ:SANA traded down $0.20 on Monday, hitting $3.46. 12,571,038 shares of the stock were exchanged, compared to its average volume of 33,846,484. The stock has a fifty day moving average of $2.40 and a 200-day moving average of $4.03. The stock has a market cap of $772.51 million, a PE ratio of -2.47 and a beta of 1.45. Sana Biotechnology, Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $12.00.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. As a group, analysts predict that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on the company. TD Cowen upgraded Sana Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday, January 8th. HC Wainwright increased their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Finally, JMP Securities downgraded shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Sana Biotechnology currently has a consensus rating of "Moderate Buy" and an average price target of $14.25.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.